10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
ABBOTT LABORATORIES | |||
Ticker: ABT Fiscal Year: 2013 | |||
Consolidated Statement of Earnings | |||
Period Ending Dec 31, 2013 10-K (Filed: Feb 21, 2014) | |||
| (In Millions) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2013 | Dec 31, 2012 | Dec 31, 2011 | |
| Net Sales | $ 21,848 | 21,494 | 21,407 |
| Cost of products sold | 10,040 | 9,817 | 10,017 |
| Amortization of intangible assets | 791 | 795 | 884 |
| Research and development | 1,452 | 1,544 | 1,512 |
| Selling, general and administrative | 6,936 | 7,444 | 7,365 |
| Total Operating Cost and Expenses | 19,219 | 19,600 | 19,778 |
| Operating Earnings | 2,629 | 1,894 | 1,629 |
| Interest expense | 157 | 347 | 359 |
| Interest income | (67) | (59) | (65) |
| Net loss on extinguishment of debt | 1,351 | ||
| Net foreign exchange (gain) loss | 50 | (25) | (20) |
| Other (income) expense, net | (32) | (25) | 119 |
| Earnings from Continuing Operations Before Taxes | 2,521 | 305 | 1,236 |
| Taxes on Earnings from Continuing Operations | 138 | (274) | 110 |
| Earnings from Continuing Operations | 2,383 | 579 | 1,126 |
| Less: Earnings from Discontinued Operations, net of tax | 193 | 5,384 | 3,602 |
| Net Earnings | 2,576 | 5,963 | 4,728 |
| Basic Earnings Per Common Share | |||
| Continuing Operations (in dollars per share) | 1.52 | 0.36 | 0.72 |
| Discontinued Operations (in dollars per share) | 0.12 | 3.40 | 2.31 |
| Net Earnings (in dollars per share) | 1.64 | 3.76 | 3.03 |
| Diluted Earnings Per Common Share | |||
| Continuing Operations (in dollars per share) | 1.50 | 0.36 | 0.72 |
| Discontinued Operations (in dollars per share) | 0.12 | 3.36 | 2.29 |
| Net Earnings (in dollars per share) | 1.62 | 3.72 | 3.01 |
| Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share (in shares) | 1,558 | 1,575 | 1,557 |
| Dilutive Common Stock Options and Awards (in shares) | 16 | 17 | 10 |
| Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options and Awards (in shares) | 1,574 | 1,592 | 1,567 |
| Outstanding Common Stock Options Having No Dilutive Effect (in shares) | 1 | 1 | 27 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
ABBOTT LABORATORIES | |||
Ticker: ABT Fiscal Year: 2013 | |||
Consolidated Statement of Comprehensive Income | |||
Period Ending Dec 31, 2013 10-K (Filed: Feb 21, 2014) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2013 | Dec 31, 2012 | Dec 31, 2011 | |
| Net Earnings | $ 2,576 | 5,963 | 4,728 |
| Less: Earnings from Discontinued Operations, net of tax | 193 | 5,384 | 3,602 |
| Earnings from Continuing Operations | 2,383 | 579 | 1,126 |
| Foreign currency translation (loss) adjustments | (239) | (181) | (523) |
| Net actuarial gains (losses) and prior service cost and credits and amortization of net actuarial losses and prior service cost and credits, net of taxes of $393 in 2013, $(253) in 2012 and $(380) in 2011 | 882 | (715) | (503) |
| Unrealized (losses) gains on marketable equity securities, net of taxes of $(10) in 2013, $11 in 2012 and $(1) in 2011 | (18) | 19 | (2) |
| Net adjustments for derivative instruments designated as cash flow hedges, net of taxes of $(13) in 2013, $(21) in 2012 and $28 in 2011 | (53) | (91) | 111 |
| Other Comprehensive Income (Loss) from Continuing Operations | 572 | (968) | (917) |
| Comprehensive Income (Loss) from Continuing Operations | 2,955 | (389) | 209 |
| Comprehensive Income from Discontinued Operations | 193 | 5,355 | 3,289 |
| Comprehensive Income | 3,148 | 4,966 | 3,498 |
| Supplemental Accumulated Other Comprehensive Income Information, net of tax as of December 31: | |||
| Cumulative foreign currency translation loss adjustments | (718) | (79) | (72) |
| Net actuarial (losses) and prior service (cost) and credits | (1,312) | (3,596) | (2,731) |
| Cumulative unrealized gains on marketable equity securities | 13 | 31 | 38 |
| Cumulative gains on derivative instruments designated as cash flow hedges | 5 | 50 | 168 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
ABBOTT LABORATORIES | |||
Ticker: ABT Fiscal Year: 2013 | |||
Consolidated Statement of Cash Flows | |||
Period Ending Dec 31, 2013 10-K (Filed: Feb 21, 2014) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2013 | Dec 31, 2012 | Dec 31, 2011 | |
| Cash Flow From (Used in) Operating Activities: | |||
| Net earnings | $ 2,576 | 5,963 | 4,728 |
| Adjustments to reconcile earnings to net cash from operating activities - | |||
| Depreciation | 928 | 1,363 | 1,395 |
| Amortization of intangible assets | 791 | 1,419 | 1,649 |
| Share-based compensation | 262 | 433 | 383 |
| Acquired in-process and collaborations research and development | 288 | 672 | |
| Investing and financing (gains) losses, net | 4 | 356 | 142 |
| Net loss on extinguishment of debt | 1,351 | ||
| Trade receivables | (113) | 36 | (670) |
| Inventories | (154) | (417) | (130) |
| Prepaid expenses and other assets | 131 | (35) | 413 |
| Trade accounts payable and other liabilities | (436) | (134) | 1,790 |
| Income taxes | (665) | (1,309) | (1,402) |
| Net Cash From Operating Activities | 3,324 | 9,314 | 8,970 |
| Cash Flow From (Used in) Investing Activities: | |||
| Acquisitions of property and equipment | (1,145) | (1,795) | (1,491) |
| Acquisitions of businesses and technologies, net of cash acquired | (580) | (706) | (273) |
| Purchases of investment securities | (10,064) | (11,998) | (5,110) |
| Proceeds from sales of investment securities | 7,839 | 8,936 | 5,649 |
| Release of restricted funds | 1,870 | ||
| Other | 21 | 3 | 16 |
| Net Cash (Used in) From Investing Activities | (3,929) | (5,560) | 661 |
| Cash Flow From (Used in) Financing Activities: | |||
| Proceeds from issuance of (repayments of) short-term debt and other | 2,086 | 784 | (1,965) |
| Proceeds from issuance of long-term debt and debt with maturities over 3 months | 9 | 14,700 | 1,000 |
| Repayments of long-term debt and debt with maturities over 3 months | (303) | (11,071) | (3,012) |
| Acquisition and contingent consideration payments related to business acquisitions | (495) | (521) | (400) |
| Transfer of cash and cash equivalents to AbbVie Inc. | (5,901) | ||
| Purchases of common shares | (1,605) | (2,364) | (77) |
| Proceeds from stock options exercised, including income tax benefit | 395 | 1,850 | 969 |
| Dividends paid | (882) | (3,183) | (2,938) |
| Net Cash (Used in) From Financing Activities | (6,696) | 195 | (6,423) |
| Effect of exchange rate changes on cash and cash equivalents | (26) | 40 | (43) |
| Net (Decrease) Increase in Cash and Cash Equivalents | (7,327) | 3,989 | 3,165 |
| Cash and Cash Equivalents, Beginning of Year | 10,802 | 6,813 | |
| Cash and Cash Equivalents, End of Year | 3,475 | 10,802 | 6,813 |
| Supplemental Cash Flow Information: | |||
| Income taxes paid | 1,039 | 1,367 | 1,782 |
| Interest paid | 148 | 576 | 545 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||
ABBOTT LABORATORIES | ||
Ticker: ABT Fiscal Year: 2013 | ||
Consolidated Balance Sheet | ||
Period Ending Dec 31, 2013 10-K (Filed: Feb 21, 2014) | ||
| (In Millions, except shares in actual) | ||
| As of | As of | |
| Dec 31, 2013 | Dec 31, 2012 | |
| Assets | ||
| Current Assets: | ||
| Cash and cash equivalents | $ 3,475 | 10,802 |
| Investments, primarily bank time deposits and U.S. treasury bills | 4,623 | 4,372 |
| Trade receivables, less allowances of - 2013: $312; 2012: $406 | 3,986 | 7,613 |
| Inventories: | ||
| Finished products | 1,866 | 2,346 |
| Work in process | 349 | 629 |
| Materials | 478 | 818 |
| Total inventories | 2,693 | 3,793 |
| Deferred income taxes | 2,528 | 2,986 |
| Other prepaid expenses and receivables | 1,504 | 1,757 |
| Current assets held for disposition | 438 | |
| Total Current Assets | 19,247 | 31,323 |
| Investments | 119 | 274 |
| Property and Equipment, at Cost: | ||
| Land | 502 | 605 |
| Buildings | 2,994 | 4,259 |
| Equipment | 8,506 | 13,111 |
| Construction in progress | 868 | 954 |
| Property and Equipment, at Cost | 12,870 | 18,929 |
| Less: accumulated depreciation and amortization | 6,965 | 10,866 |
| Net Property and Equipment | 5,905 | 8,063 |
| Intangible Assets, net of amortization | 5,735 | 8,588 |
| Goodwill | 9,772 | 15,774 |
| Deferred Income Taxes and Other Assets | 2,109 | 3,213 |
| Non-current Assets Held for Disposition | 66 | |
| Total Assets | 42,953 | 67,235 |
| Liabilities and Shareholders' Investment | ||
| Current Liabilities: | ||
| Short-term borrowings | 3,164 | 2,082 |
| Trade accounts payable | 1,026 | 1,797 |
| Salaries, wages and commissions | 906 | 1,428 |
| Other accrued liabilities | 3,500 | 6,788 |
| Dividends payable | 341 | 221 |
| Income taxes payable | 175 | 655 |
| Current portion of long-term debt | 9 | 309 |
| Current liabilities held for disposition | 386 | |
| Total Current Liabilities | 9,507 | 13,280 |
| Long-term Debt | 3,388 | 18,085 |
| Post-employment Obligations and Other Long-term Liabilities | 4,784 | 9,057 |
| Non-current Liabilities Held for Disposition | 7 | |
| Commitments and Contingencies | ||
| Shareholders' Investment: | ||
| Preferred shares, one dollar par value Authorized - 1,000,000 shares, none issued | ||
| Common shares, without par value Authorized - 2,400,000,000 shares Issued at stated capital amount - Shares: 2013: 1,685,827,096; 2012: 1,675,930,484 | 12,048 | 11,755 |
| Common shares held in treasury, at cost - Shares: 2013: 137,728,810; 2012: 99,262,992 | (6,844) | (5,591) |
| Earnings employed in the business | 21,979 | 24,151 |
| Accumulated other comprehensive income (loss) | (2,012) | (3,594) |
| Total Abbott Shareholders' Investment | 25,171 | 26,721 |
| Noncontrolling Interests in Subsidiaries | 96 | 92 |
| Total Shareholders' Investment | 25,267 | 26,813 |
| Total Liabilities and Shareholders' Investment | 42,953 | 67,235 |
| External Links | |
| ABBOTT LABORATORIES (ABT) Fiscal Year 2013 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |